Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1983 Dec 1;158(6):2095–2107. doi: 10.1084/jem.158.6.2095

Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors

PMCID: PMC2187158  PMID: 6644239

Abstract

Injection of DBA/2, C57Bl/6, or BALB/c mice with antibody to mouse interferon alpha/beta enhanced the i.p. transplantability of six different murine tumors, as manifested by an increase in the percentage of tumor-bearing mice and a decrease in survival time. The effect was observed in mice injected with antibody to interferon raised in three sheep, a goat, and a rabbit, but not with sheep antibody to "impurities" present in the mouse interferon preparations or with normal sheep or goat globulins. The enhancement in transplantability was most marked when tumor cells had been previously passaged in vitro and were of low tumorigenicity. Analysis of some of the experimental conditions using interferon-sensitive and interferon-resistant lines of Friend erythroleukemia cells (FLC) showed that the enhancing effect was observed over a wide range of tumor cell inocula, was directly related to the amount of antibody to interferon injected and was most pronounced when antibody was administered at the time of tumor cell injection. Enhancement was also observed when FLC were injected subcutaneously (s.c.). Antibody did not act directly on the tumor cells in vitro. Although we were unable to demonstrate any biologically active interferon in mice before or after tumor cell inoculation, the results suggest that endogenous interferon is present and plays a role in inhibiting the transplantability of some murine tumors in immunocompetent mice.

Full Text

The Full Text of this article is available as a PDF (909.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Affabris E., Jemma C., Rossi G. B. Isolation of interferon-resistant variants of Friend erythroleukemia cells: effects of interferon and ouabain. Virology. 1982 Jul 30;120(2):441–452. doi: 10.1016/0042-6822(82)90044-7. [DOI] [PubMed] [Google Scholar]
  2. Affabris E., Romeo G., Belardelli F., Jemma C., Mechti N., Gresser I., Rossi G. B. 2-5A synthetase activity does not increase in interferon-resistant Friend leukemia cell variants treated with alpha/beta interferon despite the presence of high-affinity interferon receptor sites. Virology. 1983 Mar;125(2):508–512. doi: 10.1016/0042-6822(83)90224-6. [DOI] [PubMed] [Google Scholar]
  3. Belardelli F., Gresser I., Maury C., Duvillard P., Prade M., Maunoury M. T. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously. Int J Cancer. 1983 May 15;31(5):649–653. doi: 10.1002/ijc.2910310518. [DOI] [PubMed] [Google Scholar]
  4. Belardelli F., Gresser I., Maury C., Maunoury M. T. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I. Int J Cancer. 1982 Dec 15;30(6):813–820. doi: 10.1002/ijc.2910300621. [DOI] [PubMed] [Google Scholar]
  5. Belardelli F., Gresser I., Maury C., Maunoury M. T. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms. Int J Cancer. 1982 Dec 15;30(6):821–825. doi: 10.1002/ijc.2910300622. [DOI] [PubMed] [Google Scholar]
  6. De Maeyer E., De Maeyer-Guignard J. Delayed hypersensitivity to Newcastle disease virus in high and low interferon-producing mice. J Immunol. 1983 May;130(5):2392–2396. [PubMed] [Google Scholar]
  7. Fauconnier B. Augmentation de la pathogénicité virale par l'emploi de sérum anti-interféron in vivo. C R Acad Sci Hebd Seances Acad Sci D. 1970 Oct 19;271(16):1464–1466. [PubMed] [Google Scholar]
  8. Gresser I., Bandu M. T., Brouty-Boyé D. Interferon and cell division. IX. Interferon-resistant L1210 cells: characteristics and origin. J Natl Cancer Inst. 1974 Feb;52(2):553–559. doi: 10.1093/jnci/52.2.553. [DOI] [PubMed] [Google Scholar]
  9. Gresser I., Bourali C. Antitumor effects of interferon preparations in mice. J Natl Cancer Inst. 1970 Aug;45(2):365–376. [PubMed] [Google Scholar]
  10. Gresser I. How does interferon inhibit tumour growth? Philos Trans R Soc Lond B Biol Sci. 1982 Sep 24;299(1094):69–76. doi: 10.1098/rstb.1982.0107. [DOI] [PubMed] [Google Scholar]
  11. Gresser I., Maury C., Bandu M. T., Tovey M., Maunoury M. T. Role of endogenous interferon in the anti-tumor effect of poly I-C and statolon as demonstrated by the use of anti-mouse interferon serum. Int J Cancer. 1978 Jan 15;21(1):72–77. doi: 10.1002/ijc.2910210113. [DOI] [PubMed] [Google Scholar]
  12. Gresser I., Maury C., Brouty-Boyé D. Mechanism of the antitumour effect of interferon in mice. Nature. 1972 Sep 15;239(5368):167–168. doi: 10.1038/239167a0. [DOI] [PubMed] [Google Scholar]
  13. Gresser I., Maury C., Kress C., Blangy D., Maunoury M. T. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. VI. Polyoma virus infection. Int J Cancer. 1979 Aug;24(2):178–183. doi: 10.1002/ijc.2910240209. [DOI] [PubMed] [Google Scholar]
  14. Gresser I., Tovey M. G., Bandu M. E., Maury C., Brouty-Boyé D. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection. J Exp Med. 1976 Nov 2;144(5):1305–1315. doi: 10.1084/jem.144.5.1305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gresser I., Tovey M. G., Maury C., Bandu M. T. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses. J Exp Med. 1976 Nov 2;144(5):1316–1323. doi: 10.1084/jem.144.5.1316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Haller O., Arnheiter H., Gresser I., Lindenmann J. Genetically determined, interferon-dependent resistance to influenza virus in mice. J Exp Med. 1979 Mar 1;149(3):601–612. doi: 10.1084/jem.149.3.601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Inglot A. D., Inglot O., Zóltowska A., Oleszak E. Effect of anti-mouse type-1 interferon globulin on the evolution of Moloney sarcoma virus induced disease in mice. Int J Cancer. 1979 Oct 15;24(4):445–449. doi: 10.1002/ijc.2910240411. [DOI] [PubMed] [Google Scholar]
  18. Reid L. M., Minato N., Gresser I., Holland J., Kadish A., Bloom B. R. Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice. Proc Natl Acad Sci U S A. 1981 Feb;78(2):1171–1175. doi: 10.1073/pnas.78.2.1171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Senik A., Gresser I., Maury C., Gidlund M., Orn A., Wigzell H. Enhancement by interferon of natural killer cell activity in mice. Cell Immunol. 1979 Apr;44(1):186–200. doi: 10.1016/0008-8749(79)90039-x. [DOI] [PubMed] [Google Scholar]
  20. Virelizier J. L., Gresser I. Role of interferon in the pathogenesis of viral diseases of mice as demonstrated by the use of anti-interferon serum. V. Protective role in mouse hepatitis virus type 3 infection of susceptible and resistant strains of mice. J Immunol. 1978 May;120(5):1616–1619. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES